Idoxifene

Idoxifene

Clinical data
Routes of administration	Oral
Pharmacokinetic data
Biological half-life	Acute: 15 hours Chronic: 23 days
Identifiers
IUPAC name 1-[2-[4-[(E)-1-(4-iodophenyl)-2-phenylbut-1-enyl]phenoxy]ethyl]pyrrolidine
Synonyms	CB-7432, SB-223030; Pyrrolidino-4-iodotamoxifen; 4-Iodopyrrolidinotamoxifen
CAS Number	116057-75-1
PubChem CID	3034011
ChemSpider	2298565
UNII	456UXE9867
KEGG	D04496
ChEMBL	CHEMBL6318
Chemical and physical data
Formula	C28H30INO
Molar mass	523.458 g/mol
3D model (Jmol)	Interactive image
SMILES CC/C(=C(/C1=CC=C(C=C1)OCCN2CCCC2)\C3=CC=C(C=C3)I)/C4=CC=CC=C4
InChI InChI=1S/C28H30INO/c1-2-27(22-8-4-3-5-9-22)28(23-10-14-25(29)15-11-23)24-12-16-26(17-13-24)31-21-20-30-18-6-7-19-30/h3-5,8-17H,2,6-7,18-21H2,1H3/b28-27- Key:JJKOTMDDZAJTGQ-DQSJHHFOSA-N

Idoxifene (INN, USAN, BAN) (former developmental code names CB-7432, SB-223030), also known as pyrrolidino-4-iodotamoxifen, is a non-steroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group which was under development for the treatment of breast cancer and postmenopausal osteoporosis but was never marketed. It reached phase III clinical trials for postmenopausal osteoporosis and phase II clinical trials for breast cancer before development was discontinued in 1999 due insufficient effectiveness in both cases.

A large-scale chemical synthesis of idoxifene has been devised.